Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Posts 16-Percent Rise in Q1 Revenue Atop R&D and Profit Growth

NEW YORK (GenomeWeb News) — Bruker BioSciences today said first-quarter revenues increased 16 percent as R&D spending rose 11 percent and profit grew 19 percent.
Total receipts for the three months ended March 31 increased to $110.5 million from $94.9 million year over year.
Product revenue increased 14 percent to $95.4 million; service revenue increased 43 percent to $15 million; and “other” revenue contracted 76 percent to $154,000.
R&D spending rose to $13.6 million from $12.3 million in the year-ago period.
CEO Frank Laukien said the company saw “strong year-over-year growth and solid improvements in our gross margins and operating income.”
Bruker said profit rose to $3.9 million from $3.3 million in the year-ago period.
Bruker said it had around $55.7 million in cash, equivalents, and short-term investments as of March 31.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.